Cargando…

Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy

Background and Objectives: Diabetes mellitus (DM) and hypertension (HT) are characterized by cell damage caused by inflammatory and metabolic mechanisms induced by alteration in reduction-oxidative status. Serum advanced oxidation protein products (AOPP) are new markers of protein damage induced by...

Descripción completa

Detalles Bibliográficos
Autores principales: Conti, Giovanni, Caccamo, Daniela, Siligato, Rossella, Gembillo, Guido, Satta, Ersilia, Pazzano, Dario, Carucci, Nicolina, Carella, Antonio, Del Campo, Giuliana, Salvo, Antonino, Santoro, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843920/
https://www.ncbi.nlm.nih.gov/pubmed/31591338
http://dx.doi.org/10.3390/medicina55100675
_version_ 1783468329963356160
author Conti, Giovanni
Caccamo, Daniela
Siligato, Rossella
Gembillo, Guido
Satta, Ersilia
Pazzano, Dario
Carucci, Nicolina
Carella, Antonio
Del Campo, Giuliana
Salvo, Antonino
Santoro, Domenico
author_facet Conti, Giovanni
Caccamo, Daniela
Siligato, Rossella
Gembillo, Guido
Satta, Ersilia
Pazzano, Dario
Carucci, Nicolina
Carella, Antonio
Del Campo, Giuliana
Salvo, Antonino
Santoro, Domenico
author_sort Conti, Giovanni
collection PubMed
description Background and Objectives: Diabetes mellitus (DM) and hypertension (HT) are characterized by cell damage caused by inflammatory and metabolic mechanisms induced by alteration in reduction-oxidative status. Serum advanced oxidation protein products (AOPP) are new markers of protein damage induced by oxidative stress. We evaluated serum levels of AOPP in a cohort of patients with DM and HT, with or without renal complications, compared with a control healthy population. Materials and Methods: The study group comprised of 62 patients with type 2 DM and 56 with HT. The 62 patients affected by DM were further distinguished in 24 subjects without renal impairment, 18 with diabetic nephropathy (DN), 20 with chronic kidney disease (CKD) stage 2–3 secondary to DN. The subgroup of 56 patients with primary HT comprised 26 subjects without renal complications and 30 with CKD (stage 2–3) secondary to HT. Thirty healthy controls, matched for age and sex, were recruited among blood donors. Results: Increased AOPP levels were found in DM patients compared with healthy subjects, although not significantly. This index was higher and more significant in patients with DN and CKD secondary to DN than in DM patients without nephropathy (p < 0.05) or controls (p < 0.0001). Patients with HT and with kidney impairment secondary to HT also had significantly higher AOPP serum levels than controls (p < 0.01 and p < 0.0001, respectively). There were no significant differences in mean AOPP levels among DM and HT patients. Conclusion: Our study showed that oxidative stress was higher in diabetic or hypertensive subjects than in healthy controls and, in particular, it appeared to be more severe in patients with renal complications. We suggest that the assessment of AOPP in diabetic and hypertensive patients may be important to predict the onset of renal failure and to open a new perspective on the adoption of antioxidant molecules to prevent CKD in those settings.
format Online
Article
Text
id pubmed-6843920
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68439202019-11-25 Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy Conti, Giovanni Caccamo, Daniela Siligato, Rossella Gembillo, Guido Satta, Ersilia Pazzano, Dario Carucci, Nicolina Carella, Antonio Del Campo, Giuliana Salvo, Antonino Santoro, Domenico Medicina (Kaunas) Article Background and Objectives: Diabetes mellitus (DM) and hypertension (HT) are characterized by cell damage caused by inflammatory and metabolic mechanisms induced by alteration in reduction-oxidative status. Serum advanced oxidation protein products (AOPP) are new markers of protein damage induced by oxidative stress. We evaluated serum levels of AOPP in a cohort of patients with DM and HT, with or without renal complications, compared with a control healthy population. Materials and Methods: The study group comprised of 62 patients with type 2 DM and 56 with HT. The 62 patients affected by DM were further distinguished in 24 subjects without renal impairment, 18 with diabetic nephropathy (DN), 20 with chronic kidney disease (CKD) stage 2–3 secondary to DN. The subgroup of 56 patients with primary HT comprised 26 subjects without renal complications and 30 with CKD (stage 2–3) secondary to HT. Thirty healthy controls, matched for age and sex, were recruited among blood donors. Results: Increased AOPP levels were found in DM patients compared with healthy subjects, although not significantly. This index was higher and more significant in patients with DN and CKD secondary to DN than in DM patients without nephropathy (p < 0.05) or controls (p < 0.0001). Patients with HT and with kidney impairment secondary to HT also had significantly higher AOPP serum levels than controls (p < 0.01 and p < 0.0001, respectively). There were no significant differences in mean AOPP levels among DM and HT patients. Conclusion: Our study showed that oxidative stress was higher in diabetic or hypertensive subjects than in healthy controls and, in particular, it appeared to be more severe in patients with renal complications. We suggest that the assessment of AOPP in diabetic and hypertensive patients may be important to predict the onset of renal failure and to open a new perspective on the adoption of antioxidant molecules to prevent CKD in those settings. MDPI 2019-10-07 /pmc/articles/PMC6843920/ /pubmed/31591338 http://dx.doi.org/10.3390/medicina55100675 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Conti, Giovanni
Caccamo, Daniela
Siligato, Rossella
Gembillo, Guido
Satta, Ersilia
Pazzano, Dario
Carucci, Nicolina
Carella, Antonio
Del Campo, Giuliana
Salvo, Antonino
Santoro, Domenico
Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy
title Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy
title_full Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy
title_fullStr Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy
title_full_unstemmed Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy
title_short Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy
title_sort association of higher advanced oxidation protein products (aopps) levels in patients with diabetic and hypertensive nephropathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843920/
https://www.ncbi.nlm.nih.gov/pubmed/31591338
http://dx.doi.org/10.3390/medicina55100675
work_keys_str_mv AT contigiovanni associationofhigheradvancedoxidationproteinproductsaoppslevelsinpatientswithdiabeticandhypertensivenephropathy
AT caccamodaniela associationofhigheradvancedoxidationproteinproductsaoppslevelsinpatientswithdiabeticandhypertensivenephropathy
AT siligatorossella associationofhigheradvancedoxidationproteinproductsaoppslevelsinpatientswithdiabeticandhypertensivenephropathy
AT gembilloguido associationofhigheradvancedoxidationproteinproductsaoppslevelsinpatientswithdiabeticandhypertensivenephropathy
AT sattaersilia associationofhigheradvancedoxidationproteinproductsaoppslevelsinpatientswithdiabeticandhypertensivenephropathy
AT pazzanodario associationofhigheradvancedoxidationproteinproductsaoppslevelsinpatientswithdiabeticandhypertensivenephropathy
AT caruccinicolina associationofhigheradvancedoxidationproteinproductsaoppslevelsinpatientswithdiabeticandhypertensivenephropathy
AT carellaantonio associationofhigheradvancedoxidationproteinproductsaoppslevelsinpatientswithdiabeticandhypertensivenephropathy
AT delcampogiuliana associationofhigheradvancedoxidationproteinproductsaoppslevelsinpatientswithdiabeticandhypertensivenephropathy
AT salvoantonino associationofhigheradvancedoxidationproteinproductsaoppslevelsinpatientswithdiabeticandhypertensivenephropathy
AT santorodomenico associationofhigheradvancedoxidationproteinproductsaoppslevelsinpatientswithdiabeticandhypertensivenephropathy